Compositions and methods for treating ocular inflammation and ocular scarring
OwnerJames Jacob Bruvall Armstrong, Cindy Mary-Lynn Hutnikinventors
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions and methods for treating ocular inflammation and ocular fibrosis and/or scarring using a cyclooxygenase 2 serine 516 acetylating agent alone or in combination with a cytosolic phospholipase A2 agonist.
Claims40
A pharmaceutical composition comprising a cyclooxygenase 2 (COX2) Ser516 acetylating agent and a cytosolic phospholipase A2 (cPLA2) agonist.
A method of decreasing ocular inflammation in a subject, comprising administering to the subject a COX2 Ser516 acetylating agent and a cPLA2 agonist.
A method of decreasing ocular fibrosis and/or scarring in a subject, comprising administering to the subject a COX2 Ser516 acetylating agent and a cPLA2 agonist.
A method of decreasing ocular collagen contraction and/or remodelling in a subject, comprising administering to the subject a COX2 Ser516 acetylating agent and a cPLA2 agonist.
A method of decreasing ocular fibroblast cellular proliferation in a subject, comprising administering to the subject a COX2 Ser516 acetylating agent and a cPLA2 agonist.
A method of resolving ocular inflammation in a subject, comprising locally administering a COX2 Ser516 acetylating agent to the subject.
A method of decreasing ocular fibrosis and/or scarring in a subject, comprising locally administering a COX2 Ser516 acetylating agent to the subject.
A method of decreasing ocular collagen contraction and/or remodelling in a subject, comprising locally administering a COX2 Ser516 acetylating agent to the subject.
A method of decreasing ocular fibroblast cellular proliferation in a subject, comprising locally administering a COX2 Ser516 acetylating agent to the subject.
Dependencies are inferred from the claim text.